On May 26, 2022, the team of Xiamen University, Hong Kong University, Wantai Biopharm and China National Institute for Food and Drug Control published online research results entitled “A live attenuated virus-based intranasal SARS-CoV-2 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2” in the international academic journal Science Bulletin.This paper reports the results of preclinical research and immune mechanism research of nasal spray influenza virus vector SARS-CoV-2 vaccine (hereinafter referred to as "nasal spray vaccine").On the same day, the Jiangsu Provincial Center for Disease Control and Prevention, Xiamen University, China National Institute for Food and Drug Control, Dongtai City Center for Disease Control and Prevention of Jiangsu Province and Beijing Wantai team published a report in the international academic journal The Lancet Respiratory Medicine. The results of a phase I and II clinical study of the vaccine were published online, entitled "Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials”.

The nasal spray influenza virus vector SARS-CoV-2 vaccine jointly developed by Xiamen University, Hong Kong University and Beijing Wantai is based on a double attenuated influenza virus vector, which carries the new coronavirus RBD gene and can be inoculated by nasal spray CA4-dNS1 -nCoV-RBD (abbreviated as dNS1-RBD) is also the world's first nasal spray preventive vaccine against SARS-CoV-2 to enter human clinical trials. The vaccine showed rapid and long-lasting protection against a variety of mutant strains in a hamster model of severe SARS-CoV-2. It can take effect quickly after 1 day of intranasal inoculation, and can provide a long-term effect of more than 9 months after two doses of intranasal inoculation The protection showed that the body weight of the hamsters in the vaccine group did not decrease significantly, and there was no obvious pathological damage to the lung tissue. The vaccine has broad-spectrum effects on various SARS-CoV-2 concerned mutants such as Omicron. In addition, mouse experiments have shown that the vaccine can also provide broad-spectrum protection against H1N1 and H5N1 influenza virus infection. Different from intramuscular injection vaccine, the immune response induced by this vaccine is mainly airway local cellular immunity and innate immunity, and the response intensity is much higher than that of peripheral blood response. The protective mechanism involves local airway innate immune response, T cell response, mucosal IgA antibody response and humoral IgG antibody responses.

About Wantai Biopharm:

Founded in 1991, Wantai Biopharm is a high-tech enterprise engaged in the research, development and production of biological diagnostic reagents and vaccines. With the pursuit of "contributing to the cause of human health", the company is committed to transforming biotechnology achievements into high-quality products to serve the public.